



## Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting

May 2, 2022

- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS<sup>®</sup> gene editing therapies

DURHAM, N.C.--(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS<sup>®</sup>-based *ex vivo* allogeneic CAR T and *in vivo* gene editing therapies, today announced that four abstracts, including one from a research and license collaboration, were accepted by the American Society of Gene & Cell Therapy (ASGCT) and will be presented as posters and oral presentations at the upcoming annual meeting on May 16-19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.

Details for the poster and oral presentations can be accessed on the ASGCT website at <https://annualmeeting.asgct.org/abstracts>.

### Oral Presentations:

**Title:** Targeting the Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo

**Date and Time:** Tuesday, May 17, 2022, 3:45 PM – 4:00 PM

**Session Title:** Gene Editing in Cancer and Complex Diseases

**Location:** Hall E

**Abstract #:** 447

**Title:** AAV-Meganuclease-Mediated Gene Targeting Achieves Efficient and Sustained Transduction in Newborn and Infant Macaque Liver<sup>1</sup>

**Date and Time:** Wednesday, May 18, 2022, 3:00 PM – 3:15 PM

**Session Title:** Presidential Symposium and Presentation of Top Abstracts

**Location:** Hall E

**Abstract #:** 811

### Poster Presentations:

**Title:** Optimization of Hydroxyacid Oxidase 1 (HAO1) Targeting ARCUS Nucleases for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

**Date and Time:** Monday, May 16, 2022, 5:30 PM - 6:30 PM

**Session Title:** Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases I

**Location & Poster Board Number:** Hall D, M-120

**Abstract #:** 239

**Title:** ARCUS Gene Editing to Eliminate MELAS-associated m.3243A>G Mutant Mitochondrial DNA

**Date and Time:** Tuesday, May 17, 2022, 5:30 PM - 6:30 PM

**Session Title:** Gene Targeting and Gene Correction II

**Location & Poster Board Number:** Hall D, Tu-66

**Abstract #:** 561

<sup>1</sup> University of Pennsylvania's Gene Therapy Program presentation sponsored by iECURE.

### About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS<sup>®</sup> genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple *ex vivo* "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220502005331/en/): <https://www.businesswire.com/news/home/20220502005331/en/>

### Investor Contact:

Mei Burris

Director, Investor Relations and Finance

[Mei.Burris@precisionbiosciences.com](mailto:Mei.Burris@precisionbiosciences.com)

### Media Contact:

Maurissa Messier  
Senior Director, Corporate Communications  
[Maurissa.Messier@precisionbiosciences.com](mailto:Maurissa.Messier@precisionbiosciences.com)

Source: Precision BioSciences, Inc.